MSB

3.21%

$1.13 mesoblast limited

fda approval, page-8

First 8 Last

Share
Profile

Follow
Busted

1,564 Posts.

153

16/05/23

19:58

Post #: 67807480
Share

Originally posted by Cato: ↑

i cant tell what the price will be.

but what i can (without giving advice) is show 3 highly likely scenarios where the share will be

a) the first one (and most pessimistic ) the share will represent EXCLUSIVELY the gains the company can have as result of commercialisation. For sure too early stages to know all aspects of productions and costs(inclusive scale)
but if u have read the several “calculations and guesses here about productions costs , size if market , participation if the market, and selling price, we talks about something in between

1.50 to 2.50 (based on 1.00 represents just represents entire IP but zero percentage if chances to other therapies)

this number sounds “low” but its not. Remember the GvHD is not a huge market and the costs of production and general business costs cant be split in huge number of units sell every month.

b) that scenario (that i believe personally) will unlock a huge list of therapies that currently is un priced as result of no approval and no safety that will be.

as soon GVHD is approved all other ones start to be seen by market as a reliable chances that also will be.
for sure not fully priced but huge optimism will take over the entire company and the initial 2.50 can easy jump to 5 in question of few days after approval.(interesting i read recent broker that start cover this share stating sometjing in this line)

c) the final scenario if price after approval , less likely but still likely because the share after so many years dragging losses created an armynof lover and haters.
this one will be in line to recover their sufferings.

doesnt sounds to me surprise if we will see 10,00
as result a huge speculation and rumours and for sure some Pharma, now a days more “in defensive” will re-visit strike some agreements.

summary
2.50
5.00
10.00

just my views

CATO

Expand

I must say your grasp of the English language has improved remarkably!

MSB Price at posting: $1.15 Sentiment: None Disclosure: Not Held
11 Upvote

1 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

There are more pages in this discussion • 18 more messages in this thread...

First 8 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.13		Change 0.035(3.21%)		Mkt cap ! $1.284B

Open	High	Low	Value	Volume
$1.09	$1.13	$1.07	$3.910M	3.535M

Buyers (Bids)

No.	Vol.	Price($)
2	27197	$1.11

Sellers (Offers)

Price($)	Vol.	No.
$1.13	43578	3

View Market Depth

No.	Vol.	Price($)
4	31763	1.100
2	33264	1.090
2	18897	1.085
2	18926	1.080
1	18000	1.075

Price($)	Vol.	No.
1.130	23400	3
1.135	1090	1
1.140	65000	4
1.145	64500	3
1.150	92314	9

Last trade - 16.10pm 27/09/2024 (20 minute delay)

MSB (ASX) Chart

fda approval, page-8

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

ACCC seeks Olam divestments before it can buy Namoi Cotton

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

fda approval, page-8

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

ACCC seeks Olam divestments before it can buy Namoi Cotton

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News